TheraCryf PLC

TCF

Company Profile

  • Business description

    TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

  • Contact

    Congleton Road
    Alderley Park
    Nether AlderleyCheshireSK10 4TG
    GBR

    T: +44 1625315090

    E: [email protected]

    https://www.evgen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 March 2026

    Employees

    9

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.0028.70-0.31%
CAC 408,147.3553.53-0.65%
DAX 4024,118.895.32-0.02%
Dow JONES (US)47,522.12109.88-0.23%
FTSE 1009,721.0635.08-0.36%
HKSE25,989.80292.89-1.11%
NASDAQ23,581.14377.33-1.57%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,548.3289.030.66%
S&P 5006,822.3468.25-0.99%
S&P/ASX 2008,881.9031.30-0.35%
SSE Composite Index3,954.7932.11-0.81%

Market Movers